The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir–ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.
This report contains market size and forecasts of Antiviral Combination Therapies in Global, including the following market information:
Global Antiviral Combination Therapies Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Antiviral Combination Therapies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
NRTI/NNRTI Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antiviral Combination Therapies include Celltrion, Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Janssen Global Services, F. Hoffmann-La Roche Ltd., Cipla, Inc. and Mylan N.V. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antiviral Combination Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antiviral Combination Therapies Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Antiviral Combination Therapies Market Segment Percentages, by Type, 2021 (%)
NRTI/NNRTI
Integrase Inhibitor/NRTI
NRTI/Protease Inhibitor
Others
Global Antiviral Combination Therapies Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Antiviral Combination Therapies Market Segment Percentages, by Application, 2021 (%)
HIV
Hepatitis
Others
Global Antiviral Combination Therapies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Antiviral Combination Therapies Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antiviral Combination Therapies revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Antiviral Combination Therapies revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celltrion, Inc.
GlaxoSmithKline plc
Gilead Sciences, Inc.
AbbVie, Inc.
Bristol-Myers Squibb Company
Janssen Global Services
F. Hoffmann-La Roche Ltd.
Cipla, Inc.
Mylan N.V.
Merck & Co., Inc.